Rachael Galvin, DO, MPH, on Understanding Barriers to Early-Phase Clinical Trial Enrollment

Video

Research published by Galvin, et al. in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

A study published in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

According to the researchers, this information could provide insight into the patient experience and also help identify misconceptions and areas for improvement in education and the clinical trial enrollment process.

“Further characterization of barriers to clinical trial enrollment in pancreatic cancer patients could be used to develop interventions aimed at addressing these perceived barriers specifically,” the authors wrote. “Tailored interventions and further research in improving clinical trial enrollment are critical to making advances in treating this aggressive malignancy.”

In an interview with CancerNetwork®, Rachael Galvin, DO, MPH, of the department of Surgery at the Swedish Medical Center, discussed the study further and what this research could lend to those who design clinical trials for this patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Reference:

Galvin R, Chung C, Achenbach A, Dziadkowiec O, Sen S. Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Eligible for Early-Phase Clinical Trials. ONCOLOGY. https://www.cancernetwork.com/view/barriers-to-clinical-trial-enrollment-in-patients-with-pancreatic-adenocarcinoma-eligible-for-early-phase-clinical-trials

Recent Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content